scholarly journals Clinical response to sodium glucose co‐transporter 2 inhibitor ipragliflozin in a patient with metastatic renal cell carcinoma

2019 ◽  
Vol 2 (5) ◽  
pp. 269-271
Author(s):  
Keita Izumi ◽  
Yasumasa Iimura ◽  
Kiyoshi Hiruma ◽  
Tsuguhiro Touma ◽  
Tetsuro Tsukamoto
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Clinical Response ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell

Possible Correlation between Some Biologic Effects and the Clinical Course in Patiens Treated with Continuous Infusion of Interleukin-2 plus Alpha-2 Interferon for Metastatic Renal Cell Carcinoma

1994 ◽  
Vol 80 (5) ◽  
pp. 348-352 ◽  
Author(s):  
Claudia Baiocchi ◽  
Giuseppe Landonio ◽  
Gabriella Balzarmi ◽  
Carlo Cacioppo ◽  
Mario Calgaro ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Continuous Infusion ◽  
Clinical Response ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Interleukin 2 ◽  
Complete Response ◽  
Antithyroid Antibodies ◽  
Biologic Effects

Background Interleukin-2 therapy is known to cause many biologic effects, which are enhanced by the administration of interferon prior to or immediately after interleukin-2 infusion. Some of these effects could be related to the clinical response. Methods Sixteen patients with metastatic renal cell carcinoma were treated with continuous infusion of interleukin-2 plus alpha-2 interferon. Differential leukocyte count and lymphocyte subset evaluation were performed every 3 days during interleukin-2 treatment. At each cycle, the presence of the following antibodies was tested: antithyroid, antinuclear, antiplatelet and antierythrocyte. Results Fifteen patients were evaluable for response. No complete response was observed. Five patients obtained partial response (33%) and 3 stable disease (20%): 2 of them underwent surgical resection of metastases and obtained complete response. Some of our patients showed a significant increase in eosinophils, CD25+ lymphocytes and antithyroid antibodies. The association of these parameters, calculated with a “score” system, was also related to a better clinical response. Conclusions Eosinophils, CD25+ lymphocytes and antithyroid antibodies could have a predictive value for the efficacy of interleukin-2 and alpha-2 interferon therapy in metastatic renal cell carcinoma.

Metastatic Renal Cell Carcinoma Treated with Purified Leukocyte Interferon. Clinical Response in Relation to Tumor DNA Content

1991 ◽  
Vol 30 (6) ◽  
pp. 713-717 ◽  
Author(s):  
N. O. Bengtsson ◽  
P. Lenner ◽  
M. Sjödin ◽  
S. O. Hietala ◽  
R. Stenling ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Clinical Response ◽  
Metastatic Renal Cell Carcinoma ◽  
Dna Content ◽  
Renal Cell ◽  
Tumor Dna

scholarly journals Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma

Cancer ◽  
2006 ◽  
Vol 106 (3) ◽  
pp. 566-575 ◽  
Author(s):  
Brian I. Rini ◽  
Vivian Weinberg ◽  
Sarah Dunlap ◽  
Alexandra Elchinoff ◽  
Nancy Yu ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Clinical Response ◽  
Interferon Alpha ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Interferon Alpha Therapy ◽  
Cox 2 ◽  
Alpha Therapy

scholarly journals Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma

Cells ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. 17
Author(s):  
Stephane Oudard ◽  
Nadine Benhamouda ◽  
Bernard Escudier ◽  
Patrice Ravel ◽  
Thi Tran ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Clinical Response ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Angiogenic Therapy ◽  
Ancillary Study ◽  
Group 2 ◽  
Preference Study ◽  
Group 1

The modulation of subpopulations of pro-angiogenic monocytes (VEGFR-1+CD14 and Tie2+CD14) was analyzed in an ancillary study from the prospective PazopanIb versus Sunitinib patient preferenCE Study (PISCES) (NCT01064310), where metastatic renal cell carcinoma (mRCC) patients were treated with two anti-angiogenic drugs, either sunitinib or pazopanib. Blood samples from 86 patients were collected prospectively at baseline (T1), and at 10 weeks (T2) and 20 weeks (T3) after starting anti-angiogenic therapy. Various subpopulations of myeloid cells (monocytes, VEGFR-1+CD14 and Tie2+CD14 cells) decreased during treatment. When patients were divided into two subgroups with a decrease (defined as a >20% reduction from baseline value) (group 1) or not (group 2) at T3 for VEGFR-1+CD14 cells, group 1 patients presented a median PFS and OS of 24 months and 37 months, respectively, compared with a median PFS of 9 months (p = 0.032) and a median OS of 16 months (p = 0.033) in group 2 patients. The reduction in Tie2+CD14 at T3 predicted a benefit in OS at 18 months after therapy (p = 0.04). In conclusion, in this prospective clinical trial, a significant decrease in subpopulations of pro-angiogenic monocytes was associated with clinical response to anti-angiogenic drugs in patients with mRCC.

Sign in / Sign up

Export Citation Format

Share Document